Imunon, Inc. (filed as Celsion Corporation) — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. The filing identifies the registrant as Celsion Corporation, traded as CLSN on Nasdaq. It describes a clinical-stage biotechnology business developing GEN-1 for ovarian cancer, ThermoDox and nucleic-acid vaccine platforms.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Licensing revenue | $125,000 | $125,000 | $250,000 | $250,000 |
| Operating expenses | $6.10 million | $5.20 million | $12.07 million | $10.70 million |
| Operating loss | $5.98 million | $5.07 million | $11.82 million | $10.45 million |
| Net loss | $6.04 million | $5.45 million | $16.52 million | $11.14 million |
| Loss per share, basic and diluted | $0.87 | $0.95 | $2.59 | $2.19 |
- Revenue was entirely licensing revenue recognized from the Hisun agreement; the company reported no meaningful product sales. Profit margins are not useful indicators given the minimal revenue and ongoing development costs.
- Six-month R&D expense rose 22.4% to $6.32 million, reflecting increased GEN-1, PLACCINE and other development costs. G&A rose 3.8% to $5.75 million. Operating expenses increased 12.8% overall.
- Six-month net loss increased by $5.38 million year over year, principally reflecting $4.55 million of first-quarter expense associated with issuing and redeeming preferred stock. Q2 net loss increased by $0.59 million.
- Cash used in operations was $13.39 million in the first half, versus $7.35 million a year earlier. Investing activities provided $14.20 million, largely from investment maturities and sales. Financing provided $6.34 million, principally from the April common-stock offering.
- At June 30, cash and equivalents were $26.74 million; available-for-sale debt securities were $15.37 million; and restricted cash was $6.00 million. Including accrued investment interest, total cash, investments and restricted cash were reported as $48.1 million. Current assets were $44.91 million, current liabilities $6.89 million, and working capital $38.0 million.
- Debt included $6.0 million principal under the SVB facility, reported net at $5.95 million after financing adjustments. A $6.0 million restricted deposit serves as collateral. Scheduled principal payments are $3.0 million in 2024 and $3.0 million in 2025. No principal was due in 2023.
Changes, outlook and key developments
- Management said available resources, together with approximately $3.5 million of expected future New Jersey net-operating-loss sales, should fund operations into 2025. This is management’s estimate, not a guarantee; the filing notes potential need for earlier or additional financing.
- In April 2022, the company raised $7.0 million gross by issuing 1,328,274 common shares. A May 2022 at-the-market agreement authorized up to $7.5 million in additional sales; no shares had been sold under that agreement in 2022 as of the filing.
- The January preferred-stock financing raised $28.5 million gross but was redeemed in March at 105% of stated value. Related fees and legal costs contributed to the $4.55 million first-half interest expense. The company also completed a 1-for-15 reverse stock split in March, citing Nasdaq bid-price compliance and financing flexibility.
- GEN-1’s Phase II OVATION 2 study remained a central development program. In June, the data safety monitoring board recommended continuing the 100 mg/m² dose, finding safety acceptable and no dose-limiting toxicities. More than 90% of planned enrollment had been reached by July 31, 2022. The filing notes that no patient in the Phase II treatment arm had yet received all 17 prescribed doses.
- ThermoDox’s Phase III OPTIMA study had been discontinued after a 2020 futility review; the company stopped follow-up in 2021. ThermoDox continues in investigator-sponsored development.
- Management cited persistent operating losses, dependence on external capital, clinical and regulatory uncertainty, patient-enrollment and supply-chain risks, COVID-19 impacts, market volatility and inflation. Financing through equity could dilute existing holders; insufficient funds could force delays, reductions or termination of programs.
- Three legal matters remained disclosed: a securities class action, a derivative shareholder suit and a books-and-records demand. The company said it intended to defend them; potential loss and any range of loss could not be determined.
Most important facts for investors to verify
- Whether the $48.1 million resource estimate and projected runway into 2025 remain reasonable, including the timing and proceeds of planned New Jersey NOL sales.
- OVATION 2 enrollment, treatment completion, safety and eventual primary endpoint results; interim surgical findings do not establish clinical benefit.
- Actual cash burn and remaining available liquidity, distinguishing unrestricted funds from the $6.0 million collateral deposit.
- Potential dilution from future equity or ATM sales, and the terms and repayment schedule of the SVB loan.
- Developments and potential financial exposure in the disclosed legal proceedings.